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ABSTRACT
Respiratory viruses (RVs) are known to be major causes of morbidity and mortality in recipients of hemato-
poietic stem cell transplants (HSCTs), but prospective long-term studies are lacking. We prospectively
screened all adult HSCT recipients (172 allogeneic [alloHSCT] and 240 autologous [autoHSCT]) who
underwent transplantation during a 4-year period (1999 to 2003) for the development of a first episode of
symptomatic upper respiratory tract infections and/or lower respiratory tract infections (LRTI) by an RV. RVs
studied were influenza A and B viruses (n  39), human respiratory syncytial virus (n  19), human adenovi-
ruses (n  11), human parainfluenza viruses 1 to 3 (n  8), human enteroviruses (n  5), human rhinoviruses
(n  3), and the recently discovered human metapneumoviruses (n  19). During the study, 51 and 32 cases
of RV symptomatic infections were identified of alloHSCT and autoHSCT recipients (2-year incidence, 29%
and 14%, respectively). Risk factors for progression of upper respiratory tract infection to LRTI included
severe (<0.2  109/L) and moderate (<0.2  109/L) lymphocytopenia in alloHSCT (P  .02) and autoHSCT
(P  .03). Death from LRTI was attributed to an RV in 8 alloHSCT recipients. Symptomatic RV had no effect
on 2-year outcomes, with the possible exception of influenza A and B virus infections in autoHSCT: these were
associated with nonrelapse mortality (P  .02). In conclusion, this prospective trial allows an estimation of the
minimum incidence of a first RV infection in adult HSCT recipients and identifies risk factors for acquisition
of an RV infection and progression to LRTI; this should aid in the design of future studies. In addition, human
metapneumovirus should be added to the potentially serious causes of RV infections in HSCT.
© 2005 American Society for Blood and Marrow Transplantation
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pNTRODUCTION
Common respiratory viruses (RVs) have been rec-
gnized as a potential cause of severe pneumonia in
.M. and R.P.P. contributed equally to the design, follow-up, data anal-
(sis, and manuscript preparation.
B & M Tecipients of hematopoietic stem cell transplants
HSCTs) [1-16]. In this patient population, these vi-
uses cause symptomatic upper respiratory tract infec-
ions (URTI) as in the general population, but they
eem to have a higher tendency to progress to severe
neumonia or lower respiratory tract infections
LRTIs), with a mortality as high as 50% to 70%
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72,3,11,17-19]. Single-center and multicenter studies
ave analyzed the characteristics and outcome of
ymptomatic RV infections by human respiratory
yncytial virus (HRSV), inﬂuenza A and B viruses
FLUAV and FLUBV), human parainﬂuenza viruses
HPIVs) 1 to 3, human rhinovirus (HRV) [20,21],
uman enteroviruses (HEVs) [20-23], and human ad-
noviruses (HAdVs). However, most studies are ret-
ospective case series of hospitalized patients only or
re small and short prospective studies in hospitalized
atients [5] or outpatients [13,24]. The epidemiology
f each of these viruses is unique and varies from one
egion to another, as does the relative proportion of
ach type of virus and the risk of developing pneumo-
ia and death. The most common RVs in all series,
owever, are HRSV, FLUAV/FLUBV, and HPIV 1
o 3. Because all of these viruses are easily transmitted
etween individuals, RV infections can be rapidly
pread in an HSCT inpatient unit or acquired in the
ommunity by outpatients during epidemics [3,19,
5,26]. Thus, a thorough analysis of incidence and risk
actors for symptomatic RV infections requires a pro-
pective study of all HSCT recipients during hospi-
alization and after discharge.
In an effort to establish the incidence, risk factors,
nd outcome of symptomatic RV infections in adult
SCT recipients in our region (Barcelona, Spain), we
erformed a prospective 4-year study of all patients
ith symptoms of URTI, LRTI, or both during their
npatient and outpatient follow-up. In addition to the
rospective testing for FLUAV/FLUBV, HRSV,
PIV 1 to 3, HAdV, HEV, and HRV, we also retro-
pectively analyzed patient samples for the presence of
uman metapneumovirus (HMPV), a newly described
ember of the Paramyxoviridae family belonging to
he Metapneumovirus genus. Since its initial descrip-
ion in 2001 [27], HMPV has been shown to be a
ommon cause of URTI and LRTI in children [28],
ut their have been no prior studies in HSCT recip-
ents.
ATIENTS AND METHODS
atient Population and Study Design
This 4-year prospective study included all adult pa-
ients who underwent an HSCT between September
999 and October 2003 at the Division of Hematology
f the Hospital de la Santa Creu i Sant Pau, Barcelona.
ll such patients who had signs and symptoms of a
RTI or LRTI in the inpatient and outpatient set-
ings underwent a detailed clinical evaluation, and
amples from the upper and/or lower respiratory tract
ere screened for RVs. After informed consent was
btained, patients with symptoms of URTI under-
ent a nasopharyngeal aspiration (NPA), whereas pa-
ients with LRTI (ie, pneumonia) underwent a bron- c
82hoalveolar lavage (BAL) when clinically possible.
atients with pneumonia but no signs of URTI did
ot undergo an NPA. A brief questionnaire, clinical
xamination, chest radiographs, or computed tomo-
raphic (CT) scans during the episode allowed us to
lassify them as URTI or LRTI. At our institution,
ince 1995 thoracic CT scans are always quickly per-
ormed in HSCT recipients with persistent fever or
espiratory symptoms with an abnormal or normal
lain chest radiograph and no identiﬁed pathogen in
he sputum. All patients with LRTIs then undergo
AL, unless the patient is in respiratory failure that
ould be aggravated by the BAL. Patients with a pos-
tive NPA for an RV (both outpatients and inpatients)
ere asked to return to the clinic (or an inpatient
esampling) at least weekly for further clinical and
adiologic assessment and microbiological analysis un-
il all symptoms resolved and the virus was cleared
rom the NPA.
icrobiological Methods
All clinical specimens were kept on ice and pro-
essed within 2 hours of sampling. Samples were pro-
essed for RVs through antigen detection by immu-
oﬂuorescence (IF), viral culture, or both. For IF
direct IF for HRSV and indirect IF for the other
iruses), the specimens were spotted onto glass slides
nd processed by standard techniques [29]. The pres-
nce of viral antigen in respiratory cells was indicated
y the appearance of characteristic intracellular apple-
reen ﬂuorescence in 1 or more cells. Labeled anti-
odies against FLUAV and FLUBV, HPIV 1 to 3,
RSV, and HAdV were used. Samples without respi-
atory epithelial cells were considered inconclusive.
or viral culture, specimens were inoculated into each
f 4 cell lines: human ﬁbroblasts (MRC5), human
pithelial cells (Hep-2 and A-549), and Madin-Darby
anine kidney cells. Viral cultures were incubated for
weeks for RVs and 4 weeks for cytomegalovirus
CMV) on a roller drum at 35°C (A-549 and Hep-2)
r in static position (MRC5 and Madin-Darby canine
idney cells). Viruses were identiﬁed on the basis of
ytopathic effects in cell cultures and conﬁrmed by
taining with ﬂuorescein-conjugated monoclonal an-
ibodies [29,30]. BAL samples were also processed for
outine aerobic, anaerobic, mycobacterial, parasitic,
nd fungal identiﬁcation techniques. Both viral cul-
ures and IF were applied for FLUAV/FLUBV,
RSV, HAdV, and HPIV 1 to 3 in all samples. The
icornaviruses (HRV and HEV) were studied by viral
ulture, and the type of HEV was later identiﬁed, as
reviously described [31]. All these techniques were
erformed in our virology laboratory on a daily basis.
In addition, duplicate specimen aliquots (approxi-
ately 100 L) from all BAL and NPA samples wereollected in a NucliSens Extractor (BioMérieux, Bar-
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Respiratory Tract Infections in HSCT Recipients
Belona, Spain) to preserve RNA and stored at 70°C.
pecimen aliquots were later shipped to a metapneu-
ovirus (MPV) reference laboratory (Vanderbilt Uni-
ersity, Nashville, TN) and analyzed by reverse-tran-
cription polymerase chain reaction (RT-PCR) and
ene sequencing for MPV, as previously described in
etail [28]. In brief, RT-PCRs were performed in
uplicate by using the OneStep RT-PCR kit (Qiagen,
alencia, CA). Primers ampliﬁed a 170–base pair
ragment of the L (polymerase) gene that is highly
onserved among HMPV isolates [27,28]. Products
ere gel-puriﬁed and cloned into a commercial plas-
id vector (Promega, Madison, WI). The nucleotide
equences of both complementary DNA strands of the
nsert were determined on an ABI 377 Prism instru-
ent in the Vanderbilt DNA Sequencing Core. Sam-
les were considered positive if they had a unique
equence or were positive in both PCR reactions.
equences were aligned to each other and to published
MPV sequences by using ClustalW alignment in
acVector (Accelrys, San Diego, CA).
efinitions
There are no widely agreed and consistently used
eﬁnitions of the signs and symptoms required for
eﬁning the presence of a URTI or LRTI in this
atient population. Thus, a variety of deﬁnitions have
een used in clinical studies, but none of these deﬁ-
itions has been assessed in detail for its reliability and
alidity. Our deﬁnitions were adapted from deﬁnitions
or symptomatic respiratory tract infections in chron-
c-care facilities [32] and from our previous experience
ith a clinical-based deﬁnition [1,33].
To precisely classify all episodes of symptomatic
espiratory tract infections, all patients who developed
espiratory symptoms (as deﬁned below) and who con-
ented to enter the study ﬁlled out daily symptom
iaries with the help of experienced nursing or med-
cal staff. To exclude allergic reactions, respiratory
ymptoms had to be present for at least 2 days for
atients to enter the study.
A URTI was deﬁned as the presence of 2 or more
f the following symptoms: rhinorrhea and sneezing,
asal/sinus congestion, otitis media, pharyngitis, or
ry cough (similar to the common cold or pharyngo-
aryngitis syndrome [32]), with a normal chest exam-
nation and chest roentgenogram. Criteria for LRTI
or pneumonia) included (1) new-onset coughing,
ith or without widespread ﬁne crepitation, rhonchi,
oarse rales, or wheezes on lung auscultation; (2) a
ew pulmonary inﬁltrate (deﬁned by a plain chest
adiograph, high-resolution CT, or both); and (3) iso-
ation of the RV(s) involved in a BAL or lung biopsy.
he presence of a copathogen was deﬁned as thesolation of the RV in addition to pathogenic bacterial e
B & M Tpecies, fungal species (such as Aspergillus species), or
ther opportunistic viruses, especially CMV.
A ﬁrst episode of infection was deﬁned as the
eriod during which the patient had symptoms of
RTI, LRTI, or both, whether or not an RV was
solated. A further episode of infection required the
resence of a symptom-free period and negativization
f the NPA for any RVs isolated during the previous
pisode. This study, however, focuses only on a ﬁrst
pisode of RV infection per patient (unless otherwise
peciﬁed), as described later in detail. A mixed viral
nfection was deﬁned by the isolation of more than 1
V during the same episode and samples. An inpatient
nosocomial) RV infection was considered when a
atient had been in the hospital for at least 3 days and
ymptoms of the infection developed during hospital-
zation. Death from pneumonia was deﬁned as death
s a result of respiratory failure during the episode of
RTI. Progression of a URTI to an LRTI was de-
ned as the onset of pneumonia in patients with a
rior or concurrent URTI, whereas patients with
neumonia without a URTI were considered as hav-
ng an isolated LRTI. Lymphocyte counts of 0.5 
09/L and 0.2  109/L were deﬁned as moderate and
evere lymphocytopenia, respectively.
nfection-Control Measures and Therapy of RV
Recommended infection-control measures were
outinely used to avoid transmission of RVs from
atient to patient and patient to hospital staff and vice
ersa [34]. At our unit, all rooms are equipped with
ositive-pressure ventilation in sealed rooms, with an
nteroom for handwashing and change of protective
lothing. High-efﬁciency particulate air ﬁltration is
ncorporated. Airﬂow is strictly monitored to ensure
hat the pressure differentials are maintained, and at
east 12 air changes per hour are performed. Micro-
iological sampling is regularly performed to detect
elevant pathogens in the air.
All health care workers, patients, and visitors with
ymptoms of URTI were required to avoid access to
npatient wards or the outpatient clinics. Symptomatic
npatients and outpatients underwent virologic testing
f NPA, as discussed previously. Inpatients with an
V infection were placed in reverse-isolation individ-
al rooms until they were both asymptomatic and
egative for RVs. Isolation rooms were equipped with
edicated stethoscopes and other equipment, and vis-
tors and health care workers were required to wear
owns and gloves and to wash their hands before and
fter all routine patient contact. However, no system-
tic measures were taken to avoid outpatient RV in-
ections during community outbreaks. Yearly inﬂu-
nza vaccination of patients, hospital staff, and family
embers were strongly recommended, according to
stablished criteria [11].
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7All patients with LRTI by HRSV and HPIV 1 to
received inhaled ribavirin (6 g/d for 5 to 7 days) with
small particle aerosol generator. For URTI and
RTI by FLUAV and no risk factors for resistance
deﬁned by prior contact with a patient with FLUAV
nfection treated with amantadine or recent use of
mantadine by the patient), oral amantadine (100 mg
wice daily for 7 to 14 days) was an accepted therapy.
rom late 1999, oseltamivir (75 mg twice daily for 5
ays) or zanamivir (one 10-mg inhalation every 12
ours for 5-10 days) was recommended for therapy of
RTI or LRTI, and these drugs were used if the
atient had risk factors for amantadine-resistant
LUAV and in all symptomatic FLUBV infections
35]. However, therapy of URTI by any RV to avoid
rogression to LRTI (preemptive therapy) was man-
atory only if the patient had recently undergone
ransplantation (before day 60) or if the patient had
ctive graft-versus-host disease (GVHD) under treat-
ent. However, in patients without these risk factors,
reating physicians were free to decide whether to
reat patients who were ambulatory with an isolated
RTI according to their own clinical judgment, be-
ause there is no formal proof of the clinical beneﬁt of
hese preemptive therapies [3,11]. Patients were also
reated with concomitant antibiotics, antifungals, or
ntivirals directed at isolated copathogens, as indicated.
tatistical Analysis
All patients were followed up until April 2004 and
ere censored before this date in case of death from
ny cause, relapse of the underlying disease that re-
uired salvage chemotherapy, or the start of condi-
ioning for a second HSCT performed within tandem
rotocols. All analyses were performed for a ﬁrst ep-
sode of RV infection in all patients to prevent bias
ntroduction by entering patients more than once in
he outcome analyses. Thus, patients were enrolled in
his study only once, but later episodes were studied
nd managed in the same manner, although they are
ot analyzed in detail herein. The incidence of LRTI
nd URTI by RV infection was calculated by using
umulative incidence estimates and taking into ac-
ount the competing risks (nonrelapse mortality
NRM] and disease relapse), and all other usual trans-
lantation outcomes were analyzed with standard
ethods [36,37]. Univariate analyses of risk factors
or symptomatic RV infections were performed with
nivariate Cox regression models, whereas multivari-
te analyses were performed with Cox proportional
azards regression. Variables with a P value of .10
ere included in the prior univariate testing. For cat-
gorical variables, the 2 statistic or Fisher exact tests
ere used to establish differences in their distribution,
hereas the Mann-Whitney U test was used to com-
are continuous variables. Tests of signiﬁcance were 2 o
84ided, with a signiﬁcance level of P  .05. Develop-
ent of an RV infection, acute (aGVHD) and chronic
VHD (cGVHD), neutropenia, or lymphocytopenia
as entered into univariate and multivariate models as
time-dependent covariate. Because risk factors for
omplications from RV infections probably differ be-
ween allogeneic and autologous HSCT recipients
alloHSCT and autoHSCT, respectively), separate
isk factor analyses were performed for each trans-
lant group. Quantitative variables were reentered as
ualitative or binary variables only if at least a trend
or statistical signiﬁcance (P  .08) was found.
The only variables analyzed for their effect on
ymptomatic RV infections and outcomes were age,
ex, disease group (leukemia/myelodysplasia versus
ymphoid malignancies), disease status (early versus
dvanced; see Table 1 for details), prior autoHSCT,
onor type (genoidentical sibling versus alternative
onors; only for alloHSCT), stem cell source (bone
arrow [BM] versus peripheral blood stem cells
PBSCs]), T-cell depletion by CD34 cell selection
only for alloHSCT), type of conditioning (myeloab-
ative versus reduced intensity; only for alloHSCT),
ime after transplantation of the RV infection (early
before day 30], intermediate [day 31 to 90], late
after day 90 to 1 year], and very late (beyond 1
ear), close household contact with children younger
han 12 years, presence of moderate and severe lym-
hocytopenia at the time of RV infection, neutropenia
0.5  109/L), type of RV isolated, donor/recipient
MV serostatus, nosocomial or outpatient infection,
se of steroids before RV infection (0.5 mg/kg daily
or 2 weeks in the previous 2 months), and develop-
ent of aGVHD or cGVHD (only for alloHSCT).
nless otherwise speciﬁed, no further variables were
xplored, to reduce the chances of identifying possible
isk factors by chance.
ESULTS
A total of 412 HSCTs were performed during the
-year study period, and the minimum follow-up was
months for all cases. Thirty-eight patients received 2
SCTs during the study period as part of protocols
hat incorporate tandem transplantations, and thus the
otal number of patients included was 386. Unless
therwise speciﬁed, the term patient refers to each
ndividual HSCT recipient. One hundred seventy-two
atients received an alloHSCT, whereas 240 received
n autoHSCT. Patient characteristics in both trans-
lant groups are shown in detail in Table 1.
icrobiological Results
During the study period, 83 alloHSCT (48%) and
4 autoHSCT (39%) recipients were sampled at least
nce by NPA, BAL, or both because they met the
c
i
N
N
o
i
a
e
R
p
p
N
T
N
M
S
P
N
S
S
D
C
S
C
C
F
D
D
R
O
D
C
*
†
‡
§ were n
Respiratory Tract Infections in HSCT Recipients
Briteria for URTI, LRTI, or both and gave their
nformed consent. The initial sample analyzed was an
PA in 137 cases, a BAL sample in 23 cases, and both
PA and BAL in 17 cases. Table 2 details the results
f the initial sample(s) analyzed.
Initial microbiological results. Overall, an RV was
able 1. Patient Characteristics and Overall Transplantation Outcomes
Variable
umber
edian age, y (range)
ex (M/F)
atient CMV seropositive (immunoglobulin G)
osocomial infections
Underlying disease
Chronic myelogenous leukemia
Acute myeloid leukemia/myelodysplasia
Acute lymphoblastic leukemia
Non-Hodgkin lymphoma/CLL
Hodgkin disease
Multiple myeloma
Other
tatus at transplantation†
Early
Advanced
econd HSCT
onor type
HLA-identical sibling
HLA-matched unrelated
Mismatched related or unrelated
lose household contact with children <12 y
tem cell source
Peripheral blood
Bone marrow
D34-selected PBSC
onditioning regimen
TBI-based ablative
Chemotherapy-only ablative
Reduced intensity
ollow-up median, d (range)
For survivors
eveloped aGVHD (% CumInc. 95% CI)
Grades II-IV
Grades III-IV
eveloped cGVHD (% CumInc, 95% CI)§
1-y extensive cGVHD
elapse incidence (95% CI)
1 y
2 y
verall survival (95% CI)
1 y
2 y
ata are n (%) unless otherwise noted.
MV indicates cytomegalovirus; CLL, chronic lymphocytic leukem
graft-versus-host disease; cGVHD, chronic GVHD; HSCT, hem
applicable; CML, chronic myelogenous leukemia.
Includes 2 syngeneic HSCTs.
Disease phase at transplantation was categorized as early (acute le
good-risk myelodysplasia, ﬁrst chronic phase chronic myelogeno
ﬁrst complete, or partial, response after chemotherapy) and ad
remission, relapsed acute leukemia or myelodysplasia, accelera
remission, refractory or relapsed lymphoid malignancy, and any
Source included both bone marrow and peripheral blood in 13 ca
A total of 29 to 172 were not evaluable for cGVHD because theydentiﬁed in 83 episodes (47%) in the initial samples, i
B & M Tnd more than 1 RV was found during the same
pisode in 16 patients (19%). Mixed viral infections by
Vs were considered coinfections if both RVs were
resent in the initial samples or were considered su-
erinfections if the new RV appeared in follow-up
PA during the episode of URTI. Details on the
llogeneic HSCT Autologous HSCT
172 240*
19-71) 49 (19-71)
105/67 143/97
78.6) 192 (80)
43) 91 (38)
12.2) 4 (1.7)
35.5) 35 (14.5)
6.4) 5 (2.1)
19.2) 66 (27.5)
8.7) 34 (14.2)
11.6) 88 (36.7)
6.4) 8 (3.3)
33.7) 148 (61.7)
66.3) 92 (38.3)
33.1) 12 (5)
84.3)
7)
8.7)
55) 115 (48)
77.9) 222 (92.5)
21.9) 18 (7.5)‡
11)
22) 40 (16.7)
12.9) 200 (82.3)
65.1)
8-1606) 297 (14-1582)
31-1606) (n  107) 356 (96-1582) (n  188)
51.7, 44.2-59.2) NA
39.4, 32.2-47.6)
15.4, 9.4-21.4)
49.5, 41.5-57.5) NA
23.1, 10.6-35.6)
9.7-23.5) 26.7 (21.9-32.5)
15.5-31.7) 42.9 (34.3-51.5)
63-77) 80.6 (74.8-86.4)
67.3-51.7) 74.2 (67.2-81.2)
Inc, cumulative incidence; CI, conﬁdence interval; aGVHD, acute
ietic stem cell transplantation; TBI, total body irradiation; NA, not
or poor-risk myelodysplasia in ﬁrst complete remission, untreated
emia, lymphoid malignancy in ﬁrst remission, multiple myeloma in
(acute leukemia or myelodysplasia in second or higher complete
d blastic phase CML, lymphoid malignancy in second or higher
tion for a second transplantation).
ot alive and progression free beyond day 100.A
44 (
135 (
74 (
21 (
61 (
11 (
33 (
15 (
20 (
11 (
58 (
114 (
57 (
145 (
12 (
15 (
95 (
134 (
38 (
19 (
38 (
22 (
112 (
445 (
698 (
97 (
75 (
30 (
86 (
40 (
16.6 (
23.6 (
70 (
59.5 (
ia; Cum
atopo
ukemia
us leuk
vanced
ted an
indica
ses.nitial RVs isolated are shown in detail in Tables 2 and
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7. For FLUAV/FLUBV, HRSV, HPIV 1 to 3, and
AdV, the initial samples were positive by both IF
nd cell culture in 54% of the samples, whereas only
F or culture was positive in 29% and 17% of cases,
espectively. As previously described, the presence of
MPV was detected retrospectively by RT-PCR, al-
hough the samples and clinical data had been col-
ected prospectively.
Follow-up microbiological results and duration of viral
hedding. Other viral and nonviral pathogens were iso-
ated from the lower respiratory tract or a follow-up
PA in many patients, as shown in detail in Table 3.
new RV was isolated during the same clinical epi-
ode but at a follow-up (not initial) sample in 5 al-
oHSCT and 4 autoHSCT recipients (RV superinfec-
ions). Thus, the total numbers of infections by the
ifferent RVs during the 83 episodes studied (includ-
ng initial coinfections and, later, superinfections)
ere 39 FLUAV/FLUBV, 19 HRSV, 16 HMPV, 11
able 2. Number and Cumulative Incidence of the Most Common Sym
Variable
o. patients sampled at least once
o. patients with a documented RV infection*
-y incidence of any documented RV infection
o. of patients with a URTI by an RV
-y incidence of URTI by an RV
o. of patients with an LRTI by an RV
-y incidence of LRTI by an RV
o. of patients with an infection by FLUAV/FLUBV
-y incidence of infection by FLUAV/FLUBV
o. of patients with an infection by HRSV
-y incidence of infection by HRSV
o. of patients with an infection by HMPV
-y incidence of infection by HMPV
o. of patients with a monomicrobial RV infection
FLUAV/FLUBV
HRSV
HAdV
HPIV 1-3
HEV
Human rhinovirus
Human metapneumovirus
o. of patients with a mixed RV infection
FLUAV/FLUBV  HRSV
FLUAV/FLUBV  HAdV
HPIV  HAdV/HEV/FLUAV
HEV  HAdV
HMPV  HAdV/HRSV/HAdV FLUAV
ata in parentheses are 95% conﬁdence intervals unless otherwise
SCT indicates hematopoietic stem cell transplantation; RV, conv
lower respiratory tract infection; HRSV, human respiratory sync
HEV, human enteovirus.
All data refer to a ﬁrst episode of RV infection(s). Twelve patients
episodes of RV infection during the study period (see text for d
P  .001.
P  .02.
P  .09.
Mixed RV infections refer to the identiﬁcation of more than 1 typAdV, 8 HPIV 1 to 3, 5 HEV, and 3 HRV. (
86Follow-up NPAs were systematically requested at
eekly intervals only for symptomatic RV infections
ith rapid diagnostic tests (IF and rapid shell vial viral
ultures for FLUAV/FLUBV, HRSV, HAdV, and
PIV 1-3). The initial RVs were isolated again in
ollow-up NPA in 36 (60%) of 60 at the 1-week
ollow-up visit, 20 (40%) of 49 at 2 weeks, and 8 (42%)
f 19 at 3 weeks: 2 (22%) of 9 patients tested positive
eyond 3 weeks, with no signiﬁcant differences be-
ween transplant groups and type of RV. The median
uration of viral shedding in patients who came to
ollow-up sampling was 2 weeks (range, 0-12 weeks).
Forty-nine (80%) of 61 patients with an initial
RTI were screened at least weekly for 2 weeks to
ocument viral clearance. In these patients, we as-
essed factors that inﬂuenced prolonged viral shed-
ing in NPA, deﬁned as a persistently positive NPA
or the initial RV for 2 weeks. In all 49 evaluable
ases, multivariate analysis found only 2 risk factors:
c RV Infections*
Allogeneic HSCT
(n  172)
Autologous HSCT
(n  240)
83 (48%) 94 (39%)
51 32
29.1 (19.1-36.7)† 14.1 (6.9-19.7)†
41 32
20.1 (11.7-28.5)† 14.1 (6.9-19.7)†
29 8
12.5 (5.1-17.9)† 2.5 (0.1-5.1)†
24 15
13.1 (7.1-19.1)‡ 6.1 (2.6-9.6)‡
12 7
7.5 (2.1-12.6)§ 2.9 (0.9-4.9)§
9 7
5.2 (1.7-9.7) 2.9 (0.9-5.2)
42 25
13/4 10/1
7 4
6 1
3 2
2 1
2 —
5 6
9 7
4 3
1 1
—/—/1 1/1/—
1 —
—/1/1 1/—/—
ed.
l respiratory virus; URTI, upper respiratory tract infection; LRTI,
rus; HMPV, human metapneumovirus; HAdV, human adenovirus;
eneic and 4 autologous transplant recipients) developed 2 or more
V during the same clinical episode.ptomati
speciﬁ
entiona
ytial vi
(8 allog
etails).1) mixed viral URTI (hazard ratio [HR], 15; 95%
Table 3. Clinical Presentation and Outcome of 83 Episodes of Clinically Symptomatic Infections by Respiratory Viruses in Posttransplantation Patients
Variable
FLUAV
(n  33) or
FLUBV (n  6)
HRSV
(n  19)
HAdV
(n  11)
HPIV 1-3
(n  8)
HEV
(n  5)
HRV
(n  3)
(Allo Only)
HMPV
(n  16)
Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto
Total related to type of HSCT, n* 24 15 12 7 7 4 4 4 3 2 3 9 7
Nosocomial infection 8 (67) 6 (40) 5 (42) 3 (43) 2 (29) 2 (50) 3 (75) — — 2 5 (56) 3 (43)
Seasonal occurrence in autumn or winter 3 (14) 1 (7) 2 (17) — 1 (14) 1 (25) — 2 (50) 1 (34) 1 2 2 (22) 1 (14)
14 (54) 8 (53) 9 (75) 6 (86) 4 (57) 2 (50) 1 (25) 1 (25) 2 (66) 1 3 (33) 3 (43)
Period after HSCT
Early (<30 d) 9 (37) 5 (33) 3 (25) 3 (43) 1 (14) 1 (25) 2 (50) 1 (25) 2 4 (44) 4 (57)
Intermediate (31-90 d) 4 (17) 5 (33) 4 (33) 3 (43) 1 (14) 1 2 (50) 1 (25) 1 (34) — 1 1 (11) 2 (29)
Late (91 d to 1 y) and very late (>1 y) 11 (46) 5 (33) 5 (42) 1 (14) 5 (71) 2 (50) — 2 (50) 2 (66) 2 (100) 4 (44) 1 (14)
Documented sites of infection
URTI only, n  50 (25/25) 11 (45) 11 (74) 4 (33) 4 (57) 3 (43) 4 (100) 1 (25) 3 (75) 2 (66) 2 (100) 3 (100) 5 (56) 6 (86)
URTI - LRTI, n  23 (16/7)
Initial URTI - LRTI, n  8 (5/3) 2 (8) 2 (13) 2 (16) 3 (43) 1 (14) — — — 1 (34) — — —
URTI followed by LRTI, n  15 (11/4) 3 (13) 2 (13) 3 (25) 1 (14) 2 (28) — 3 (75) — 2 (22) 1 (14)
LRTI only, n  14 (13/1) 8 (34) — 3 (25) — 1 (14) — — 1 (25) 2 (22) —
Symptoms in patients with URTI† n  30 n  13 n  10 n  7 n  5 n  2 n  10
Rhinorrhea 22 (73) 9 (69) 9 (90) 7 (100) 5 (100) 2 (100) 9 (90)
Nasal congestion and/or sneezing 19 (63) 9 (69) 10 (100) 6 (86) 5 (100) 2 (100) 10 (100)
Sinusitis 2 (7) — — — — — 2 (20)
Pharyngitis-laryngitis 6 (20) — 2 (20) 2 (29) — 2 (100) 6 (60)
Frontal headache 2 (7) 5 (38) 3 (30) — 2 (40) — 6 (60)
Conjunctivitis — 3 (23) 2 (20) — 4 (67) 2 (100) 2 (20)
Tracheobronchial cough (no pneumonia) 14 (47) 4 (40) 3 (30) 6 (36) 4 (80) — 4 (40)
Fever (>37.5°C) 13 (43) 2 (15) 5 (50) 4 (57) 5 (100) 2 (100) 6 (60)
Number of weekly follow-up NPA performed‡
1 wk 12/18 7/14 6/9 4/5 1/4 1/3 2/4 2/2 NA NA NA
2 wk 7/11 2/4 4/5 2/2 1/1 0/3 0/3 0/2
>3 wk 5/10 1/2 2/7 1/2 1/1 0/1 —
Specific antiviral therapy: total treated n (%) 16 (67) 7 (47) 10 (83) 4 (57) 4 (57) — 2 (50) 1 (25) NA NA NA
Death attributed to RV (n, % with LRTI) 3 (23) 0/4 2 (25) 0/3 2 (50) — 0/3 6/1 0/1 — 2 (50) 0/1
No other copathogens found 1 — 1 — 1 — — —
Other copathogens involved 2 — 1 — 2 (50) —
Invasive aspergillosis 2 — 2 —
Grant-negative bacilli 1 — — —
Cytomegalovirus 1 — 1 — 1 — 1 —
Data are n (%) unless otherwise indicated.
There were 51 alloHSCTs and 32 auto HSCTs.
HSCT indicates hematopoietic stem cell transplantation; RV, respiratory virus; URTI, upper respiratory tract infection; LRTI, lower respiratory tract infection; NPA, nasopharyngeal aspirate; NA, not
applicable.
*The number of respiratory viruses was 101 in 83 episodes, because mixed viral episodes (1 respiratory virus isolated) occurred in 9 alloHSCT and 7 autoHSCT recipients (detailed in Table 2).
†Speciﬁc URTI symptoms for each virus include both alloHSCT and autoHSCT because there were no differences in any symptom between the 2 transplant groups.
‡Numbers refer to still-positive NPAs in follow-up samples/number of patients who were resampled at each time point.
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7onﬁdence interval [CI], 2.5-91; P  .003); and (2)
onearly disease status at transplantation (HR, 6; 95%
I, 1.47-23; P .02). In autoHSCT (n 19 evaluable
ases), the only possible risk factor identiﬁed was
ixed viral URTI (HR, 11; 95% CI, 0.99-130; P 
053), whereas in alloHSCT (n  30 evaluable cases),
possible risk factors were identiﬁed in multivariate
nalysis: (1) mixed viral URTI (HR, 33; 95% CI,
.4-4765; P .03), (2) nonearly disease status at trans-
lantation (HR, 18; 95% CI, 1.3-245; P .03), and (3)
rior aGVHD grades II to IV (HR, 8; 95% CI, 1.02-
4; P  .05). Of note, use of oseltamivir/zanamivir,
mantadine, or inhaled ribavirin (see section on ther-
py) showed a trend toward reducing prolonged viral
hedding in univariate testing (5/14 [36%] patients
reated versus 11/16 [69%] in untreated patients;
 .07).
ncidence of RV Infections
Allogeneic HSCT. Fifty-one alloHSCT recipients
ested positive for an RV virus during the study pe-
iod, and more than 1 RV was identiﬁed during the
ame episode in 14 (9 coinfections and 5 superinfec-
ions) of these patients, as detailed in Table 2. The
-year cumulative incidence of a ﬁrst episode of RV
nfection was 29.1% (95% CI, 19.1%-36.7%), and 29
atients developed conﬁrmed LRTI by RVs (inci-
ence, 12.5%; 95% CI, 5.1%-17.9%). The median
nset of symptomatic RV infections was 169 days
range, 3-963 days). In univariate analysis, risk factors
or a higher risk of developing any RV infection were
1) close household contact with children younger
han 12 years (41% versus 16%; P  .007), (2) alter-
ative donor (nongenoidentical sibling) HSCT (58%
ersus 28%; P  .04), and (3) cGVHD (33% versus
9%; P  .03). Trends were found for prior au-
oHSCT (P  .08), CD34 cell selection (P  .07),
nd reduced-intensity conditioning (P  .08). In mul-
ivariate analysis, only close household contact with
hildren younger than 12 years (HR, 2.5; 95% CI,
.3-5; P  .009) and cGVHD (HR, 1.5; 95% CI,
.03-2.04; P  .03) were associated with the risk of
eveloping an RV infection (Figure 1). When the ﬁnal
nivariate and multivariate models were applied to
osocomial and outpatient respiratory tract infections,
lose household contact with children remained an
ndependent risk factor in both subgroups. In addition
o a ﬁrst episode of RV infection, 8 alloHSCT recip-
ents developed 2 or more episodes of RV infection
all initially URTIs) during the study period. Seven
pisodes occurred during a different winter season,
nd 1 occurred during the same winter. The RVs
nvolved were FLUAV/FLUBV in 4 cases and HRSV,
PIV 3, HAdV, HEV, and HRV in 1 case each. Two
f these 8 URTIs progressed to LRTI, and 1 patient
ied from HAdV and FLUAV pneumonia. y
88Autologous HSCT. Thirty-two autoHSCT recipi-
nts tested positive for an RV virus, and more than 1
V was identiﬁed during the same episode in 11 (7
oinfections and 4 superinfections) of these patients.
he 2-year cumulative incidence of symptomatic RV
nfections was 14.1% (95% CI, 6.9%-19.7%), and
nly 8 patients developed conﬁrmed LRTI by an RV
incidence, 2.5%; 95% CI, 0.1%-5.1%). The median
ime to onset of symptomatic RV infections was 164
ays (range, 1-1222 days). Thus, although the inci-
ence of both URTI and LRTI was much higher in
lloHSCT recipients (Table 2), the median time to a
rst episode was the same in both groups. In univar-
ate analysis, risk factors for a higher risk of develop-
ng any RV infection in autoHSCT were (1) close
ousehold contact with children younger than 12
igure 1. Cumulative incidence of development of a ﬁrst docu-
ented episode of respiratory virus infection in allogeneic trans-
lant recipients. A, Incidence in 86 patients who developed
GVHD according to whether they had (heavy line) or did not have
light line) close household contact with children (12 years): this
ncidence was 45% and 19%, respectively, on day 720. B, Inci-
ence in 57 evaluable patients who did not develop cGVHD ac-
ording to whether they had (heavy line) or did not have (light line)
lose household contact with children (12 years): this incidence
as 29% and 11%, respectively, on day 720.ears (20% versus 9%; P  .05), (2) advanced disease
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Respiratory Tract Infections in HSCT Recipients
Btatus at transplantation (18% versus 6%; P .03), (3)
M as the stem cell source (24% versus 11%; P 
06), and (3) patient CMV seropositivity (17% versus
%; P .05). In multivariate analysis, close household
ontact with children younger than 12 years (HR, 2.2;
5% CI, 1.1-6.9; P  .05) and advanced disease status
HR, 2.9; 95% CI, 1.1-7.7; P .03) were the only risk
actors identiﬁed (Figure 2). In addition to a ﬁrst
pisode of RV infection, 4 autoHSCT recipients de-
eloped 2 or more episodes of RV infection during the
tudy period, but all of these episodes occurred during
different winter season. The RVs involved were
LUAV in 2 cases and HRSV, HPIV 3, and HRV in
case each. One case of FLUAV URTI progressed to
RTI, from which the patient fully recovered.
The most commonly isolated RVs in both trans-
lant groups were FLUAV/FLUBV (n  39), HRSV
igure 2. Cumulative incidence of development of a ﬁrst docu-
ented episode of respiratory virus infection in autoHSCT recip-
ents. A, Incidence in 92 patients with advanced underlying disease
tatus at transplantation according to whether they had (heavy line)
r did not have (light line) close household contact with children
12 years): this incidence was 18% and 9%, respectively, on day
720. B, Incidence in 148 patients with early underlying disease
tatus at transplantation according to whether they had (heavy line)
r did not have (light line) close household contact with children
12 years): this incidence was 10% and 4%, respectively, on day
720.n  19), and MPV (n  16). The proportion of L
B & M Tosocomial and community-acquired RV infections
id not differ signiﬁcantly between transplant groups
nosocomial infections: 24 [47%] alloHSCTs versus
2 [38%] autoHSCTs). Additionally, no clustering of
osocomial infections occurred during the study pe-
iod, and both these and community-acquired symp-
omatic RV infections occurred during community
utbreaks by each speciﬁc RV analyzed (Figure 1A).
he proportion of episodes that occurred before day
90 was somewhat higher in autoHSCT: early (days
to 30) plus intermediate (days 31 to 90) infec-
ions, 56% versus 76% in alloHSCT and autoHSCT,
espectively, and late (day91 to 1 year) plus very late
1 year after transplantation) infections, 44% versus
4%, respectively (P  .08).
RTI (Pneumonia) by an RV: Number, Risk
actors, and Outcome
Of the 83 patients with a ﬁrst episode of RV
nfection, 37 developed a ﬁrst LRTI during the study
pisode (29 alloHSCTs and 8 autoHSCTs). Eleven
atients had only an LRTI, without a concomitant or
rior URTI (11 and 0 cases, respectively). Eight pa-
ients had both a URTI and an LRTI at initial diag-
osis (6 and 3 cases, respectively), whereas 15 patients
ad an initial URTI that progressed to an LRTI
uring the study episode (12 and 5 cases, respectively).
n 9 patients with an LRTI, more than 1 RV was
solated from lower respiratory tract samples (5 allo-
SCTs and 4 autoHSCTs). BAL conﬁrmed the pres-
nce of an RV in the lower respiratory tract in 24
65%) cases of LRTIs (all 14 cases of initial LRTI, 4/8
ases of initial URTI and LRTI, and 6/15 secondary
RTIs from a prior URTI), whereas 13 additional
ases (all alloHSCTs) were documented in lung tissue.
Allogeneic HSCT. In univariate analysis, risk factors
or developing an LRTI were (1) advanced disease
tatus at transplantation (17% versus 5%; P .01), (2)
lternative donor (nongenoidentical sibling) HSCT
28% versus 5%; P  .05), (3) prior autoHSCT (28%
ersus 6%; P  .04), and (4) cGVHD (16% versus
%; P  .01). Trends were found for grades II to IV
GVHD (18% versus 8%; P  .08) and stem cell
ource (40% for cord blood versus 9% for PBSC
ersus 11% for BM; P  .10). In multivariate analysis,
nly alternative donors (HR, 1.7; 95% CI, 1.05-2.9;
 .05) and cGVHD (HR, 1.6; 95% CI, 1.1-2.6;
 .05) were associated with the risk of developing an
RTI.
When all 172 allografts were analyzed, a strong
isk factor for developing an LRTI by an RV was
aving documented a recent (6 weeks) URTI by the
ame virus or viruses. Eighteen (44%) of 41 patients
ith a URTI developed an LRTI by the same RV,
hereas 11 (8%) of 131 with no documented URTI
eveloped an LRTI (2-year cumulative incidence of
RTI: 30% [95% CI, 2%-34%] versus 8% [95% CI,
789
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7%-13%], respectively; P  .01). This variable, how-
ver, was not introduced in multivariate Cox models
ven though it was highly signiﬁcant in univariate
esting, because variables that predispose to the devel-
pment of LRTI may also increase the risk of URTI
nd/or the progression of URTI to LRTI (mainly
lternative [nongenoidentical sibling] donors, cGVHD,
nd aGVHD).
Death was attributed to an LRTI by an RV in 8
28%) of the 29 alloHSCT recipients. The RVs in-
olved in fatal cases were FLUAV/FLUBV (3/13
23%] pneumonias), HRSV (2/8 [25%] pneumonias),
AdV (1/4 [25%] pneumonias), and MPV (2/4 [50%]
neumonias). However, signiﬁcant copathogens were
ound in 5 of the 8 deaths from LRTI (see Table 3 for
etails).
Autologous HSCT. In univariate analysis, risk fac-
ors for developing an LRTI were stem cell source
3% for BM versus 0% for PBSCs; P  .01) and male
ex (5% versus 0%; P  .05). Because of the small
umber of events and risk factors in univariate testing,
multivariate analysis could not be performed. None
f the 8 autoHSCT recipients with pneumonia died.
Other pathogens found in LRTI. A copathogen
nown to be deﬁnitively involved in opportunistic
RTIs was identiﬁed in BAL or lung samples in 5
lloHSCT recipients (2 with gram-negative bacilli, 2
ith invasive pulmonary aspergillosis, 1 with CMV, and
with both CMV and invasive pulmonary aspergillosis).
n autoHSCT, only 1 case of invasive pulmonary as-
ergillosis coexisted with an RV (Table 3).
isk for Progression of URTI to LRTI
As described previously, 23 (33%) of the 70 pa-
ients who presented with symptoms of a URTI either
ad pneumonia (n  8) or progressed to pneumonia
n  15) during the follow-up period (18/41 [44%]
lloHSCT and 5/29 [17%] autoHSCT; P  .05).
Allogeneic HSCT. The median interval between
RTI and the ﬁrst signs of LRTI was 7 days (range,
-32 days). In univariate analysis, risk factors for pro-
ression of a URTI to LRTI included (1) severe lym-
hocytopenia (0.2  109/L) at the onset of the
RTI (50% versus 20%; P  .04), (2) alternative
onor (nongenoidentical sibling) HSCT (39% versus
2%; P  .05), (3) disease group (12% in leukemia/
yelodysplasia versus 50% in lymphoid malignancies;
 .05), (4) prior grade II to IV aGVHD (44% versus
2%; P  .04), and (5) prior extensive cGVHD (40%
ersus 20%; P .04). Trends were found for stem cell
ource (30% for PBSCs versus 11% for BM; P  .10)
nd type of RV isolated (3/4 HPIV 1-3, 3/7 HRSV,
/5 HAdV, 3/14 FLUAV/FLUBV, and 2/7 MPV;
 .10). In multivariate analysis, only severe lympho-
ytopenia (HR, 7.3; 95% CI, 1.3-40.9; P  .02) and
rade II to IV aGVHD (HR, 3.8; 95% CI, 1.1-15.5; (
90 .05) were associated with the risk of developing an
RTI from a prior URTI.
Autologous HSCT. Because only 5 autoHSCT re-
ipients had a URTI that progressed to an LRTI, risk
actors could not be reliably determined. However,
he presence of moderate lymphocytopenia (0.5 
09/L) at the onset of the URTI seemed to increase
he risk (31% versus 9%; P  .03), and a trend was
bserved for the presence of neutropenia (0.5 
09/L) at the onset of infection (33% versus 0%; P 
10). Additionally, the type of RV involved also
eemed to increase this risk (5/25 with FLUAV/
LUBV, HRSV, or MPV versus 0/7 for other RVs).
s in alloHSCT, a strong association was found be-
ween developing an LRTI by an RV and a recent
RTI by the same virus or viruses. Eight (25%) of 32
atients with a URTI developed an LRTI by the same
V, whereas 0 of 208 with no documented URTI
eveloped an LRTI (2-year cumulative incidence of
RTI: 31% [95% CI, 6%-56%] versus 0%, respec-
ively; P  .0001).
ffect of Symptomatic RV Infections on NRM
nd Survival
Development of an LRTI by any RV (introduced
s a time-dependent variable) was associated with the
00-day and 2-year NRM estimates in all 412 patients
n univariate analysis. Nine of 37 patients with and 26
f 375 without an LRTI by an RV experienced NRM.
he 100-day and 2-year cumulative incidences of
RM were 9.2% (95% CI, 1.2%-17.2%) and 22%
95% CI, 11%-33%), respectively, in patients with
RTI by an RV and 3.7% (95% CI, 0.1%-7.9%) and
4% (95% CI, 10%-18%), respectively, in patients
ithout this complication (P  .01). However, when
lloHSCT and autoHSCT recipients were analyzed
eparately, LRTI by an RV had no effect on early or
ate NRM (data not shown). However, in all 412
atients, the 1- and 2-year overall survival (OS) for
atients who developed an RV (all infections or
RTIs) did not differ from the OS in those who did
ot develop any episode of RV infection. Neverthe-
ess, in multivariate analysis of OS, symptomatic RV
nfections were kept in all models and analyzed as
ime-dependent variables, as indicated in “Statistical
nalysis.”
In alloHSCT recipients, variables that decreased
-year OS (ﬁnal multivariate model) were (1) devel-
pment of invasive aspergillosis (HR, 5.6; 95% CI,
.7-8.6; P .01), (2) advanced disease phase (HR, 1.9;
5% CI, 1.01-4.4; P  .05), (3) CD34 cell–selected
llogeneic PBSC transplant (HR, 3.3; 95% CI, 1.7-
.6; P  .01), (4) development of grade III/IV
GVHD (HR, 1.4; 95% CI, 1.03-1.9; P .05), and (5)
ot developing cGVHD (HR, 3.5; 95% CI, 2.5-4.9;
 .001). Variables that increased the 2-year NRMﬁnal multivariate model) were (1) development of
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Respiratory Tract Infections in HSCT Recipients
Bnvasive aspergillosis (HR, 3.3; 95% CI, 1.2-9.3; P 
04), (2) CD34 cell–selected allogeneic PBSC trans-
lant (HR, 2.1; 95% CI, 1.12-2.86; P  .04), (3)
eveloping aGVHD grade III/IV (HR, 6.6; 95% CI,
.5-11.6; P  .01), and (4) use of conventional my-
loablative conditioning (ie, not receiving a reduced-
ntensity conditioning regimen; HR, 3.2; 95% CI,
.1-9.06; P  .05).
In autoHSCT recipients, the only variables ana-
yzed that decreased the 2-year OS (ﬁnal multivariate
odel) were (1) advanced disease phase (HR, 2.1; 95%
I, 1.1-5.4; P .04) and (2) development of FLUAV/
LUBV infection (HR, 3.2; 95% CI, 1.3-8.1; P 
02). Variables found to increase the 2-year NRM
ﬁnal multivariate model) were (1) development of
LUAV/FLUBV infection (HR, 2.2; 95% CI, 0.99-
.2; P  .06) and (2) age60 years (HR, 3.8; 95% CI,
.1-9.1; P  .03).
MPV infections. Details on the incidence and clin-
cal characteristics of all the ﬁrst episodes of each RV
nfection are shown in detail in Tables 2 and 4 and are
hus not described in detail separately in the text.
owever, a brief description of MPV infections would
e useful because this is, to our knowledge, the ﬁrst
escription of these infections in HSCT recipients.
PV was isolated in 16 (9%) of 177 samples tested
5/40 [13%] BALs and 11/154 [7%] NPAs), and
oinfections with other RVs were seen in 3 (19%)
ases. MPV infections occurred at all time periods
fter transplantation in both alloHSCT (n  9) and
utoHSCT (n  7) recipients, with a 2-year incidence
f 5.2% (95% CI, 1.7%-9.75%) and 3% (95% CI,
.9%-5.2%), respectively. Fifty percent of the infec-
ions were community acquired, and MPV pneumonia
as documented in 4 (44%) of 9 and 1 (14%) of 7
lloHSCT and autoHSCT recipients, respectively. As
ith the other viruses studied, LRTIs were preceded
y a URTI in 3 (60%) of 5 cases of pneumonia.
ecause these infections were diagnosed retrospec-
ively, follow-up NPAs were not obtained to assess the
uration of viral shedding.
ISCUSSION
Our study provides several relevant observations
bout the incidence, clinical course, and complications
f symptomatic RV infections after HSCT, with the
mportant fact that all patients who underwent trans-
lantation over the 4-year study period with respira-
ory tract infections were systematically screened for
he presence of the major RVs and followed a stan-
ardized clinical protocol. More importantly, the
earch for RVs was uniformly applied not only on
PA, but also on all BAL, biopsy, and autopsy spec-
mens obtained throughout the study. Because 80% of
ur HSCT recipients who develop LRTI undergo i
B & M TAL and/or postmortem lung examination, the ob-
erved results of LRTIs by RVs are probably an ac-
urate measure of the true frequency of these infec-
ions. Additionally, detailed case report forms were
lled in by the patients and by the treating medical
nd nursing staff. This study design may give more
xact information than previous retrospective or brief
rospective studies focused on adult and/or pediatric
atients with a speciﬁc documented RV infection;
hese studies focused mainly on hospitalized patients
r analyzed mostly symptomatic RV infections that
ccurred during the ﬁrst 3 to 4 months after HSCT
1-16,38]. Transversal studies, which do not allow
etermining risk factors for acquiring RV infections,
ave also analyzed all symptomatic RV infections di-
gnosed over a given time period, ranging from a few
onths [13] to 1 to 7 years [6,12,14,15,39]. A few
tudies have estimated the incidence of and risk factors
or acquiring URTI and/or LRTI by retrospectively
nalyzing patients with a documented RV infection
uring a given time period and comparing them with
ll transplant patients during the same time period
2,4,16,33,40-42]. Ljungman et al. [12] performed a
-year prospective multicenter study of RV infections
cquired early after HSCT within the European
roup for Blood and Marrow Transplantation Infec-
ious Diseases Working Party. Surprisingly, only 40
ymptomatic RV infections were reported in 1863
ransplant patients, and this did not allow appropriate
isk factor analyses. This low frequency was probably
consequence of low sampling in cases of URTI
nd/or nonstandardized laboratory studies for RVs.
hese 40 cases, however, were combined with an
dditional 53 cases obtained transversally in an effort
o at least deﬁne risk factors for LRTI and death
mong infected patients.
Even with such a prospective intensive monitoring
f all symptomatic patients, surely many RV infec-
ions, especially URTIs, were not diagnosed. Several
easons may lead to underestimating the true inci-
ence of both URTI and LRTI by any RV. An im-
ortant reason is the fact that we studied only symp-
omatic infections, and patients with mild symptoms
f URTI are unlikely to attend the emergency outpa-
ient clinic. Additionally, patients who live far away
rom our hospital and were referred for transplanta-
ion would be more likely to seek attention at their
ocal center for common cold or ﬂulike symptoms.
inally, more sensitive diagnostic testing with PCR-
ased methods for all known RVs would have un-
oubtedly identiﬁed more cases of symptomatic RV
nfections, which may double with very sensitive PCR
echniques [13,43-46]. However, PCR methods for
ach type of RV are not standardized, and thus we
hose to use viral culture and IF for the current study,
xcept, of course, for HMPV infections. Thus, the
ncidences we found surely represent only a fraction of
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Table 4. Interaction in Each Transplant Group between Lymphocytopenia, Acute Grades II to IV GVHD (Only in AlloHSCT), Type of Respiratory Virus, and Having Received (or Not) Speciﬁc Antiviral
Therapy with the Risk of Progression to LRTI in 61 Patients with Initial Isolated URTI by FLUAV/FLUBV, HRSV, HPIV 1 to 3, and Adenovirus (n/N, %)
Transplant Type
Received Specific
Antiviral Therapy
for the URTI
Progression of initial URTI to LRTI*
Overall
Lymphocytopenia
Acute GVHD
Grades II to IV Type of Respiratory Virus Isolated†
Yes (n  7) No (n  25) Yes (n  13) No (n  19) FLUA/FLUBV (n  27) HRSV (n  13) HAdV (n  9) HPIV 1-3 (n  7)
Allogeneic HSCT
(n  32) 9/32 (28) 4/7 (57)‡ 5/25 (20)‡ 6/13 (46)§ 3/19 (16)§ 3/14 (21) 3/7 (43) 2/5 (40) 1/4 (25)
Yes (n  13) 3/13 (23) 2/4 (50) 1/9 (11) 2/4 (50) 1/9 (11) 1/5 (20) 2/6 (33) 1/1 0/1
No (n  23) 6/19 (33) 2/3 (67) 4/16 (25) 4/9 (44) 2/10 (20) 3/9 (33) 1/1 1/4 1/3
Autologous
HSCT
(n  29) 4/29 (14) 3/11 (27)§ 1/18 (6)§ NA NA 2/13 (15) 1/5 (20) 1/4 (25) 0/3
Yes (n  6) 3/6 (50)¶ 2/2 (100) 1/4 (25) NA NA 2/3 (66) 1/2 (50) 0/0 0/1
No (n  23) 1/23 (4)¶ 1/9 (11) 0/14 (0) NA NA 0/10 0/3 1/4 0/2
HSCT indicates hematopoietic stem cell transplantation; URTI, upper respiratory tract infection; LRTI, lower respiratory tract infection; NA, not applicable; FLUA/FLUBV  human inﬂuenza
A/inﬂuenza B; HRSV, human respiratory syncytial virus; HAdV, human adenovirus; HPIV, human parainﬂuenza virus.
*Progression to LRTI for each RV was (alloHSCT and autoHSCT combined) (1) FLUA/BV, 5/27 (19%); (2) HRSV, 4/12 (33%); (3) HAdV, 2/9 (22%); (4) HPIV 1–3, 3/7 (43%); not included in this
table: MPV, 3/14 (21%).
†Four autoHSCT recipients had 2 different RVs isolated from the same nasopharyngeal aspirates and are not included in these columns.
‡P  .07.
§P  .10.
See text and Table 3 for details on antiviral therapy.
¶P  .02.
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Respiratory Tract Infections in HSCT Recipients
Bhe actual cases of RV infections, especially uncom-
licated isolated URTIs, experienced by our trans-
lant patients.
With these caveats in mind, symptomatic RV in-
ections were common after HSCT in our patient
ohorts and were associated with a relatively high
ncidence of progressing to LRTI. URTIs and LRTIs
y all RVs were seen among both autoHSCT and
lloHSCT recipients. Recipients of alloHSCT seemed
o have a higher risk, but, again, this may be the result
f several biases that lead to more common sampling
f alloHSCT recipients, who are probably more likely
o attend the outpatient clinic with symptoms of a
RTI. An interesting ﬁnding was that an apparent
isk factor for acquiring an RV infection after HSCT
as having close household contact with children. To
ur knowledge, this observation has not been previ-
usly reported. Nevertheless, this is a logical ﬁnding,
ecause children develop many RV infections and are
ery contagious because of their high viral excretion
nd intimate contact with their close relatives [47].
nfortunately, this risk factor is not modiﬁable in
eal-life clinical practice.
URTIs per se are often not perceived as a poten-
ially serious problem for patients and HSCT physi-
ians, but pneumonia (LRTI) is appropriately per-
eived as a serious complication, because several
tudies have found that mortality from an LRTI with
he most commonly identiﬁed RVs may be high. Most
uthors place great emphasis on avoiding patient in-
ection with rigorous infection-control policies and, if
URTI is diagnosed, in avoiding the progression to
n LRTI, although this may not be possible with
urrent therapies. In our study, the incidence of a ﬁrst
RTI by an RV was 13% in alloHSCT and 2.5% in
utoHSCT recipients; in alloHSCT recipients, the
evelopment of pneumonia was due primarily to the
resence of moderate to severe GVHD, alternative
onor transplantation, and severe lymphocytopenia.
o large differences between the main RVs were
bserved, but the number of LRTIs per each speciﬁc
V was small. With respect to currently available
ntiviral agents that may be active against certain RVs,
nhaled ribavirin is by far the most commonly recom-
ended antiviral agent for HRSV and HPIV 1 to 3,
hereas FLUAV and FLUBV are both susceptible to
he neuraminidase inhibitors oseltamivir and zanami-
ir. Amantadine is active against FLUAV, but resistant
trains develop rapidly in vivo [48]. However, most
etrospective studies have failed to show any signiﬁ-
ant beneﬁt of inhaled ribavirin on the progression of
n initial URTI to pneumonia by HRSV and HPIV 1
o 3 [3,4,6,11,26,42,49-51]. With respect to FLUAV/
LUBV, small patient series have also failed to show
ny clear beneﬁt of preemptive therapy with amanta-
ine/rimantadine or the neuraminidase inhibitors (os-
ltamivir/zanamivir), but the data available are very i
B & M Tcant [2,39,52]. Because early therapy with oseltamivir
as been shown to obtain clinically relevant beneﬁts in
arge randomized trials in immunocompetent adults
48,53], we might see a beneﬁt in our immunocom-
romised hosts if adequately designed prospective tri-
ls were performed. Our results on preemptive ther-
py of URTI were in line with previous studies.
ecause lymphocytopenia and grade II to IV aGVHD
re strongly interrelated variables and were the main
isk factors for progression to pneumonia in our study,
e analyzed whether there were interactions between
hese variables, speciﬁc antiviral therapy, and risk for
rogression to LRTI in each transplant group and
ype of RV (detailed in Table 4). Although the sub-
roups were too small to allow deﬁnitive conclusions,
atients with lymphocytopenia or aGVHD seemed to
e equally likely to develop pneumonia whether they
ere treated with antivirals or not, thus raising doubts
bout the value of preemptive therapy in patients with
RTIs. Preemptive therapy, however, may be useful
or epidemiologic reasons, as described later in this
iscussion.
Few studies have analyzed risk factors for LRTI by
hese viruses in HSCT. Of note, the presence of
ymphocytopenia was an independent risk factor for
RTI and/or progression of URTI to LRTI in the
ew studies that included a reliable multivariate anal-
sis. In a multicenter 1-year prospective study per-
ormed by the Infectious Disease Working Party of
he European Group for Blood and Marrow Trans-
lantation [12], lymphocytopenia was the most signif-
cant variable predisposing to LRTI when all RVs are
nalyzed together, but especially in HRSV infections.
wo large retrospective studies from Seattle also iden-
iﬁed lymphocytopenia as an independent risk factor
or LRTI in patients with HRSV [54] and FLUAV/
LUBV [2] infections. Recently, our group published
nother prospective study based on a cohort of pa-
ients with hematologic diseases (who did not receive
ransplants), and it concluded that lymphocytopenia
redicted the presence of RV pneumonia at any mo-
ent and had a borderline signiﬁcance for the pro-
ression to pneumonia from a prior URTI [1].
In our current study, mortality from LRTI was rel-
tively low and usually occurred in the presence of ag-
ressive copathogens (6/8 deaths). The outcome of pa-
ients with pneumonia (especially by HRSV, HPIV 1-3,
nd FLUAV/FLUBV) has been historically poor,
ith mortality rates ranging from 50% to 85%
5,6,10,11,24,33,55-58]. Whimbey et al. [5] reported
hat the risk of LRTI and death was closely related to the
nterval between transplantation and the appearance of
ymptoms: 70% of patients developed LRTI if the
nfection was acquired during the ﬁrst month after trans-
lantation. However, recent studies from the same insti-
ution and others have reported an attributable mortality
n LRTIs by these RVs to be much lower (10%-30%),
793
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7ith little or no effect of the period afterHSCT in which
t develops. These ﬁndings are similar to ours [11-
6,41,54,59-62]. Because there is no clear evidence that
urrently available antiviral therapy reduces the mortal-
ty from LRTI by any RV, this reduction in mortality
ay be due to improvements in supportive care and
eductions in the rates of copathogens (mainly pulmo-
ary aspergillosis andCMVpneumonia). In fact, in some
revious studies, the absence of aggressive copathogens
n LRTIs seemed to translate into lower mortality,
ather than the use of antiviral therapy [11,42]. The
oexistence of RV pneumonia and other aggressive pul-
onary infections in HSCT recipients is not surprising,
nd the incidence may actually increase if survival of
hese patients increases; however, establishment of a
ood and long-lasting immune system does not improve
n parallel with survival.
It should be highlighted, however, that most stud-
es performed to date have focused only on early
RM in which an RV LRTI is implicated, but its
ffect on long-term outcomes has not been measured.
notable exception is the retrospective analysis of
arainﬂuenza virus infections by the Seattle group [4],
n which 1-month NRM after an LRTI was relatively
ow (35%), but the 6-month NRM was 75%. Thus,
V infections may have indirect local or systemic
ffects that predispose to later NRM. This may be
artly due to an increased risk of LRTI by other
opathogens, but it may also indicate that symptom-
tic RV infections are surrogate markers of something
lse that has not been analyzed, or it may be a com-
ination of several variables.
Because most patients with an initial URTI by
LUAV/FLUBV, HRSV, HPIV 1 to 3, and HAdV
49/61; 80%) were screened at least weekly for 2
eeks to document viral clearance, we were able to
ssess the factors that inﬂuenced prolonged viral shed-
ing. Few prior studies have reported detailed data on
he duration of viral shedding. A recent retrospective
tudy from Seattle that included 51 HSCT recipients
ith a URTI by FLUAV/FLUBV [2] identiﬁed 3
ossible risk factors for prolonged shedding: al-
oHSCT versus autoHSCT, steroid therapy 1 mg/
g/d, and not receiving antiviral therapy, especially
seltamivir. Machado et al. [39] found prolonged
hedding in 12 (48%) of 25 patients with HRSV, 2
9%) of 23 with FLUAV/FLUBV, and 1 (13%) of 8
ith HPIV 1 to 3 URTIs. Unfortunately, risk factors
ere not described, although all patients with
LUAV/FLUBV were treated with oseltamivir or
mantadine, whereas only a few patients with HRSV
eceived therapy [15]. In contrast, we found only a
rend for a reduction of the duration of viral shedding
n patients treated with speciﬁc antiviral therapy (pro-
onged shedding in 5/14 [36%] patients treated versus
1/16 [69%] in untreated patients; P  .07), but it
hould be stressed that this was a prospective obser- s
94ational study and not a controlled treatment study,
nd therapy was given (according to protocol and
tandard hospital guidelines) mostly to sicker or high-
r-risk patients, as previously speciﬁed. However, the
rend toward reduced viral shedding is a positive ﬁnd-
ng that may decrease the spread of these viruses and
he risk of generating drug-resistant strains [48,63].
The most novel observation in our study was the
elatively high incidence of HMPV URTI and LRTI in
ur patients. Because this virus was discovered recently
27], there are currently no published data on the impli-
ations of HMPV in HSCT recipients, except for a
ingle case report [64]. Among healthy children, and
robably also healthy adults, a signiﬁcant portion of
itherto unexplained viral respiratory tract illnesses can
ow be attributed to the human MPV [28,65,66]. Sev-
ral surveys on the burden of disease of HMPV infection
ave been conducted in various immunocompetent
tudy groups and have suggested that clinically it is in-
istinguishable from HRSV and FLUAV/FLUBV in-
ections, with recurrent epidemics during the winter
onths. Although there are no published data on MPV
nfections in our speciﬁc geographic area (Barcelona,
hich lies in the western Mediterranean), data from the
eighboring Basque country, as in other areas in Europe
nd worldwide, have conﬁrmed its presence in URTI
nd LRTI [67,68]. Thus, despite the lack of prior data, it
s reasonable to believe that HMPV will infect immu-
ocompromised individuals at least as commonly as the
eneral population. For obvious reasons, MPV infec-
ions in our patients were studied retrospectively in
tored frozen aliquots and with a PCR technique, which
as performed in an experienced reference laboratory
28]. Thus, the incidence of HMPV infection is not
omparable to the other RVs studied on site prospec-
ively by IF and viral cultures. However, the 16 cases
dentiﬁed suggest that its clinical relevance in adult
SCT recipients is as important as that of HRSV,
LUAV/FLUBV, and the other common RVs. Of the
6 HMPV infections, 5 were LRTIs, and 2 alloHSCT
ecipients died from this infection, as detailed in Table 3.
ecently, researchers from Seattle reported an abstract
f a retrospective study of 211 BALs from 162 HSCT
ecipients: MPV was identiﬁed in 5 patients (3%) and 8
AL samples (3.8%). More importantly, 4 of these pa-
ients died with the clinical and autopsy diagnosis of
diopathic pneumonia syndrome [69]. Thus, MPV must
urely be added to the list of the potentially lethal RVs in
ur patient population.
In conclusion, this prospective study allowed an es-
imation of the minimum incidence of a ﬁrst RV infec-
ion in adult HSCT recipients. It identiﬁed risk factors
or acquisition of an RV infection, prolonged viral shed-
ing in URTI, and development of URTI and progres-
ion to LRTI, which should aid in the design of future
tudies. In addition, the recently discovered HMPV
s
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Bhould be added to the potentially serious causes of
ymptomatic RV infections in HSCT worldwide.
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